U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C4H3FN2O2
Molecular Weight 130.0772
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Fluorouracil

SMILES

FC1=CNC(=O)NC1=O

InChI

InChIKey=GHASVSINZRGABV-UHFFFAOYSA-N
InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)

HIDE SMILES / InChI

Molecular Formula C4H3FN2O2
Molecular Weight 130.0772
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.229877.com/article/2013/1127/article_33601.html

Tegafur (INN, BAN, USAN) is a chemotherapeutic fluorouracil prodrug used in the treatment of cancers. It is a component of the combination drugs tegafur/uracil and tegafur/gimeracil/oteracil. UFT is an anticancer medication composed of a fixed molar ration (1:4) of tegafur and uracil. This drug is commonly used in the treatment of head and neck cancer, gastric cancer, colorectal cancer, hepatic cancer, gallbladder cancer, bile-duct cancer, pancreatic cancer, lung cancer, breast cancer, bladder cancer, prostatic cancer, or uterine cervical cancer. In the body, tegafur is converted into 5-fluorouracil (5-FU), the active antineoplastic metabolite. The mechanism of cytotoxicity of 5-FU is thought to be derived from the fact that 5-fluoro-deoxyuridine-monophosphate (FdUMP), the active metabolite of 5-FU, competes with deoxyuridine-monophosphate (dUMP), thereby inhibiting thymidylate synthase and subsequently DNA synthesis. Another active metabolite of 5-FU, 5-fluorouridine-triphosphate (FUTP) is integrated into cellular RNA, inhibiting RNA function. Uracil, when combined with tegafur, enhances the antitumor activity of 5-FU due to higher 5-FU concentrations in the tumor tissue versus normal surrounding tissue compared with tegafur alone. Uracil inhibits degradation of the released 5-FU. The combination of these two drugs enhances the antitumor activity of Tegafur.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
29.5 µM [IC50]
16.0 nM [IC50]
Target ID: CHEMBL613860
43.8 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
UFT E combination granule T100 / T150

Approved Use

in the treatment of head and neck cancer, gastric cancer, colorectal cancer, hepatic cancer, gallbladder cancer, bile-duct cancer, pancreatic cancer, lung cancer, breast cancer, bladder cancer, prostatic cancer, or uterine cervical cancer.
Primary
UFT E combination granule T100 / T150

Approved Use

in the treatment of head and neck cancer, gastric cancer, colorectal cancer, hepatic cancer, gallbladder cancer, bile-duct cancer, pancreatic cancer, lung cancer, breast cancer, bladder cancer, prostatic cancer, or uterine cervical cancer.
Primary
UFT E combination granule T100 / T150

Approved Use

in the treatment of head and neck cancer, gastric cancer, colorectal cancer, hepatic cancer, gallbladder cancer, bile-duct cancer, pancreatic cancer, lung cancer, breast cancer, bladder cancer, prostatic cancer, or uterine cervical cancer.
Primary
UFT E combination granule T100 / T150

Approved Use

in the treatment of head and neck cancer, gastric cancer, colorectal cancer, hepatic cancer, gallbladder cancer, bile-duct cancer, pancreatic cancer, lung cancer, breast cancer, bladder cancer, prostatic cancer, or uterine cervical cancer.
Primary
UFT E combination granule T100 / T150

Approved Use

in the treatment of head and neck cancer, gastric cancer, colorectal cancer, hepatic cancer, gallbladder cancer, bile-duct cancer, pancreatic cancer, lung cancer, breast cancer, bladder cancer, prostatic cancer, or uterine cervical cancer.
Primary
FLUOROURACIL

Approved Use

Fluorouracil is indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum Adenocarcinoma of the Breast Gastric Adenocarcinoma Pancreatic Adenocarcinoma

Launch Date

1962
Primary
FLUOROURACIL

Approved Use

Fluorouracil is indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum Adenocarcinoma of the Breast Gastric Adenocarcinoma Pancreatic Adenocarcinoma

Launch Date

1962
Primary
FLUOROURACIL

Approved Use

Fluorouracil is indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum Adenocarcinoma of the Breast Gastric Adenocarcinoma Pancreatic Adenocarcinoma

Launch Date

1962
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2046.2 ng/mL
80 mg 2 times / day multiple, oral
dose: 80 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: GIMERACIL
TEGAFUR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
11.49 ng/mL
1 g 2 times / day steady-state, topical
dose: 1 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
278 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10786 ng × h/mL
80 mg 2 times / day multiple, oral
dose: 80 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: GIMERACIL
TEGAFUR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
22.39 ng × h/mL
1 g 2 times / day steady-state, topical
dose: 1 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
205 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.5 h
80 mg 2 times / day multiple, oral
dose: 80 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: GIMERACIL
TEGAFUR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.24 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
47.7%
TEGAFUR serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
90%
FLUOROURACIL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
DLT: Ataxia...
Other AEs: Anorexia, Nausea...
Dose limiting toxicities:
Ataxia (grade 3, 4 patients)
Other AEs:
Anorexia (3 patients)
Nausea (severe, 2 patients)
Vomiting (2 patients)
Stomatitis (severe, 1 patient)
Diarrhea (3 patients)
Weakness (1 patient)
Hair loss (1 patient)
Peeling (1 patient)
Sources:
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Other AEs: Ataxia, Anorexia...
Other AEs:
Ataxia (3 patients)
Anorexia (4 patients)
Nausea (severe, 2 patients)
Vomiting (3 patients)
Stomatitis (mild, 3 patients)
Diarrhea (2 patients)
Weakness (2 patients)
Hair loss (2 patients)
Loss of eyelashes (1 patient)
Peeling (2 patients)
Peeling (2 patients)
Sources:
2800 mg/m2 1 times / week multiple, intravenous
Dose: 2800 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2800 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3, 1 patient)
Sources:
3000 mg/m2 1 times / week multiple, intravenous
Dose: 3000 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3000 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3-4, 2 patients)
Sources:
3250 mg/m2 1 times / week multiple, intravenous
Dose: 3250 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3250 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3-4, 2 patients)
Sources:
0.5 % 1 times / day multiple, topical
Recommended
Dose: 0.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Disc. AE: Irritation skin...
AEs leading to
discontinuation/dose reduction:
Irritation skin (12%)
Sources:
1250 mg 1 times / 2 days multiple, oral
Dose: 1250 mg, 1 times / 2 days
Route: oral
Route: multiple
Dose: 1250 mg, 1 times / 2 days
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
500 mg single, oral
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Anaemia, Angina unstable...
Other AEs:
Anaemia (serious, 2 patients)
Angina unstable (serious, 5 patients)
Arrhythmia (serious, 2 patients)
Arteriosclerosis coronary artery (serious, 1 patient)
Atrial flutter (serious, 3 patients)
Atrial tachycardia (serious, 1 patient)
Atrial thrombosis (serious, 1 patient)
Cardiac disorder (serious, 1 patient)
Cardiac failure congestive (serious, 7 patients)
Cardio-respiratory arrest (serious, 2 patients)
Coronary artery stenosis (serious, 1 patient)
Myocardial ischaemia (serious, 1 patient)
Palpitations (serious, 1 patient)
Pericarditis (serious, 1 patient)
Ventricular tachycardia (serious, 2 patients)
Vertigo (serious, 1 patient)
Vertigo positional (serious, 1 patient)
Disorder vestibular (serious, 1 patient)
Goitre (serious, 1 patient)
Inappropriate antidiuretic hormone secretion (serious, 1 patient)
Abdominal hernia (serious, 1 patient)
Colitis ischaemic (serious, 1 patient)
Gastritis (serious, 2 patients)
Haemorrhoids (serious, 1 patient)
Impaired gastric emptying (serious, 1 patient)
Hernia inguinal (serious, 1 patient)
Intestinal obstruction (serious, 2 patients)
Obstruction gastric (serious, 1 patient)
Oesophageal obstruction (serious, 1 patient)
Pancreatitis (serious, 1 patient)
Vomiting (serious, 1 patient)
Adhesion (serious, 1 patient)
Chest discomfort (serious, 1 patient)
Generalised oedema (serious, 1 patient)
Non-cardiac chest pain (serious, 3 patients)
Cholelithiasis (serious, 2 patients)
Hepatitis alcoholic (serious, 1 patient)
Arthritis infective (serious, 1 patient)
Bacteraemia (serious, 1 patient)
Bronchopneumonia (serious, 1 patient)
Cholecystitis infective (serious, 1 patient)
Clostridium difficile infection (serious, 3 patients)
Cystitis (serious, 1 patient)
Endocarditis (serious, 1 patient)
Incision site cellulitis (serious, 1 patient)
Infection (serious, 2 patients)
Septic shock (serious, 1 patient)
Upper respiratory tract infection (serious, 1 patient)
Urinary tract infection (serious, 6 patients)
Viral infection (serious, 1 patient)
Device toxicity (serious, 1 patient)
Fall (serious, 11 patient)
Hip fracture (serious, 2 patients)
Intentional overdose (serious, 1 patient)
Limb injury (serious, 1 patient)
Lower limb fracture (serious, 1 patient)
Meniscus injury (serious, 2 patients)
Periprosthetic fracture (serious, 1 patient)
Postoperative fever (serious, 1 patient)
Procedural nausea (serious, 1 patient)
Procedural pain (serious, 1 patient)
Radiation oesophagitis (serious, 1 patient)
Road traffic accident (serious, 2 patients)
Traumatic haematoma (serious, 1 patient)
Vascular bypass dysfunction (serious, 1 patient)
Blood glucose increased (serious, 1 patient)
Electrocardiogram abnormal (serious, 1 patient)
Haemoglobin decreased (serious, 1 patient)
International normalised ratio increased (serious, 2 patients)
White blood cell count increased (serious, 1 patient)
Dehydration (serious, 5 patients)
Diabetes mellitus inadequate control (serious, 2 patients)
Failure to thrive (serious, 3 patients)
Hyperglycaemia (serious, 2 patients)
Hyponatraemia (serious, 3 patients)
Iron deficiency (serious, 1 patient)
Arthralgia (serious, 3 patients)
Bursa disorder (serious, 1 patient)
Exostosis (serious, 1 patient)
Muscular weakness (serious, 1 patient)
Osteoarthritis (serious, 10 patients)
Tendonitis (serious, 1 patient)
Basal cell carcinoma (serious, 1 patient)
Benign salivary gland neoplasm (serious, 1 patient)
Brain neoplasm (serious, 2 patients)
Colorectal cancer (serious, 1 patient)
Diffuse large B-cell lymphoma stage IV (serious, 1 patient)
Haemangioma (serious, 1 patient)
Lung neoplasm malignant (serious, 4 patients)
Malignant melanoma (serious, 3 patients)
Metastases to central nervous system (serious, 1 patient)
Metastatic squamous cell carcinoma (serious, 1 patient)
Neuroendocrine carcinoma (serious, 1 patient)
Prostate cancer (serious, 5 patients)
Prostate cancer recurrent (serious, 1 patient)
Renal cancer (serious, 2 patients)
Renal cancer metastatic (serious, 1 patient)
Renal cell carcinoma (serious, 1 patient)
Salivary gland cancer (serious, 1 patient)
Squamous cell carcinoma (serious, 2 patients)
Basilar artery stenosis (serious, 1 patient)
Cognitive disorder (serious, 1 patient)
Dementia (serious, 4 patients)
Epilepsy (serious, 1 patient)
Headache (serious, 1 patient)
Hypoaesthesia (serious, 1 patient)
Parkinson's disease (serious, 2 patients)
Haemorrhage subarachnoid (serious, 1 patient)
Transient ischaemic attack (serious, 4 patients)
Transient ischaemic attack (serious, 4 patients)
Dementia vascular (serious, 1 patient)
Alcohol abuse (serious, 2 patients)
Binge drinking (serious, 1 patient)
Completed suicide (serious, 1 patient)
Confusional state (serious, 1 patient)
Delirium tremens (serious, 1 patient)
Depression (serious, 3 patients)
Mental disorder (serious, 1 patient)
Mental status changes (serious, 2 patients)
Post-traumatic stress disorder (serious, 1 patient)
Suicidal behaviour (serious, 1 patient)
Suicidal ideation (serious, 3 patients)
Hydronephrosis (serious, 2 patients)
Nephropathy (serious, 1 patient)
Renal failure chronic (serious, 1 patient)
Erectile dysfunction (serious, 1 patient)
Prostatic haemorrhage (serious, 1 patient)
Prostatitis (serious, 1 patient)
Chronic obstructive pulmonary disease (serious, 9 patients)
Dyspnoea (serious, 2 patients)
Dyspnoea exertional (serious, 1 patient)
Haemoptysis (serious, 1 patient)
Pleural effusion (serious, 1 patient)
Pulmonary embolism (serious, 3 patients)
Respiratory failure (serious, 1 patient)
Rash (serious, 1 patient)
Angioplasty (serious, 1 patient)
Cholecystectomy (serious, 1 patient)
Coronary angioplasty (serious, 1 patient)
Elective procedure (serious, 1 patient)
Hip arthroplasty (serious, 1 patient)
Knee arthroplasty (serious, 1 patient)
Medical device removal (serious, 1 patient)
Oesophagogastric fundoplasty (serious, 1 patient)
Parotidectomy (serious, 1 patient)
Wound treatment (serious, 1 patient)
Aortic aneurysm (serious, 2 patients)
Aortic occlusion (serious, 1 patient)
Arterial occlusive disease (serious, 1 patient)
Femoral artery occlusion (serious, 1 patient)
Labile hypertension (serious, 1 patient)
Orthostatic hypotension (serious, 2 patients)
Disorder peripheral vascular (serious, 1 patient)
Lymphadenopathy (below serious, 1 patient)
Vertigo (below serious, 1 patient)
Adrenal mass (below serious, 1 patient)
Eye haemorrhage (below serious, 1 patient)
Eye irritation (below serious, 3 patients)
Eye pain (below serious, 2 patients)
Eye pruritus (below serious, 1 patient)
Eye swelling (below serious, 4 patients)
Photophobia (below serious, 1 patient)
Visual acuity reduced (below serious, 1 patient)
Abdominal pain upper (below serious, 2 patients)
Cheilitis (below serious, 1 patient)
Diarrhoea (below serious, 3 patients)
Diverticulum (below serious, 1 patient)
Dyspepsia (below serious, 1 patient)
Gastrooesophageal reflux disease (below serious, 1 patient)
Gingival pain (below serious, 1 patient)
Nausea (below serious, 5 patients)
Fatigue (below serious, 3 patients)
Feeling of body temperature change (below serious, 1 patient)
Hernia (below serious, 1 patient)
Local swelling (below serious, 1 patient)
Malaise (below serious, 1 patient)
Pain (below serious, 11 patient)
Syringe issue (below serious, 1 patient)
Temperature intolerance (below serious, 1 patient)
Tenderness (below serious, 2 patients)
Vessel puncture site haematoma (below serious, 1 patient)
Hypersensitivity (below serious, 1 patient)
Seasonal allergy (below serious, 1 patient)
Bronchitis (below serious, 4 patients)
Cellulitis (below serious, 1 patient)
Folliculitis (below serious, 1 patient)
Fungal infection (below serious, 1 patient)
Herpes zoster (below serious, 2 patients)
Infection (below serious, 2 patients)
Influenza (below serious, 1 patient)
Nasopharyngitis (below serious, 5 patients)
Oral herpes (below serious, 1 patient)
Pneumonia (below serious, 2 patients)
Accidental exposure to product (below serious, 1 patient)
Arthropod sting (below serious, 1 patient)
Fall (below serious, 5 patients)
Laceration (below serious, 1 patient)
Muscle rupture (below serious, 1 patient)
Body temperature increased (below serious, 1 patient)
Emergency care examination (below serious, 1 patient)
Gout (below serious, 1 patient)
Arthralgia (below serious, 1 patient)
Back pain (below serious, 3 patients)
Foot deformity (below serious, 1 patient)
Musculoskeletal pain (below serious, 1 patient)
Neck pain (below serious, 1 patient)
Pain in extremity (below serious, 1 patient)
Polymyalgia rheumatica (below serious, 1 patient)
Basal cell carcinoma (below serious, 1 patient)
Haemangioma (below serious, 1 patient)
Transitional cell carcinoma (below serious, 1 patient)
Burning sensation (below serious, 1 patient)
Dizziness (below serious, 4 patients)
Headache (below serious, 5 patients)
Hypoaesthesia (below serious, 2 patients)
Syncope (below serious, 1 patient)
Tunnel vision (below serious, 1 patient)
Abnormal dreams (below serious, 1 patient)
Anxiety (below serious, 1 patient)
Psychotic disorder (below serious, 1 patient)
Sleep disorder (below serious, 22 patients)
Dysuria (below serious, 1 patient)
Haemorrhage urinary tract (below serious, 1 patient)
Pollakiuria (below serious, 1 patient)
Chronic obstructive pulmonary disease (below serious, 1 patient)
Nasal congestion (below serious, 1 patient)
Productive cough (below serious, 1 patient)
Pulmonary mass (below serious, 1 patient)
Rhinorrhoea (below serious, 1 patient)
Sinus disorder (below serious, 1 patient)
Acne (below serious, 5 patients)
Blister (below serious, 2 patients)
Blood blister (below serious, 1 patient)
Decubitus ulcer (below serious, 1 patient)
Dermatitis (below serious, 447 patients)
Dermatitis allergic (below serious, 1 patient)
Hyperhidrosis (below serious, 2 patients)
Photosensitivity reaction (below serious, 5 patients)
Post inflammatory pigmentation change (below serious, 1 patient)
Scab (below serious, 1 patient)
Seborrhoea (below serious, 1 patient)
Dermatitis seborrhoeic (below serious, 2 patients)
Skin discomfort (below serious, 1 patient)
Skin haemorrhage (below serious, 3 patients)
Skin tightness (below serious, 1 patient)
Skin ulcer (below serious, 1 patient)
Urticaria (below serious, 1 patient)
Oral surgery (below serious, 1 patient)
Wound drainage (below serious, 1 patient)
Haemorrhage (below serious, 7 patients)
Temporal arteritis (below serious, 1 patient)
Sources:
111.6 mg/m2 1 times / day steady, oral
RP2D
Dose: 111.6 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 111.6 mg/m2, 1 times / day
Sources:
unhealthy, 54 years
Health Status: unhealthy
Age Group: 54 years
Sex: M+F
Sources:
Other AEs: Fatigue, Nausea...
Other AEs:
Fatigue (grade 1-2, 3 patients)
Nausea (grade 1-2, 2 patients)
Sources:
248 mg/m2 1 times / day steady, oral
RP2D
Dose: 248 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 248 mg/m2, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Other AEs: Granulocytopenia, Nausea...
Other AEs:
Granulocytopenia (grade 4, 1 patient)
Nausea (grade 3, 1 patient)
Thrombocytopenia (grade 3, 1 patient)
Vomiting (grade 1-2, 5 patients)
Fatigue (grade 1-2, 4 patients)
Diarrhoea (grade 1-2, 4 patients)
Sources:
139.5 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 139.5 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 139.5 mg/m2, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3-4, 3 patients)
Sources:
279 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 279 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 279 mg/m2, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
DLT: Granulocytopenia...
Dose limiting toxicities:
Granulocytopenia (grade 4, 4 patients)
Sources:
124 mg/m2 1 times / day steady, oral
Dose: 124 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 124 mg/m2, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3-4, 3 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hair loss 1 patient
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Peeling 1 patient
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Weakness 1 patient
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Vomiting 2 patients
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Anorexia 3 patients
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Diarrhea 3 patients
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Ataxia grade 3, 4 patients
DLT, Disc. AE
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Stomatitis severe, 1 patient
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Nausea severe, 2 patients
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Loss of eyelashes 1 patient
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Diarrhea 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Hair loss 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Peeling 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Peeling 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Weakness 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Ataxia 3 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Vomiting 3 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Anorexia 4 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Stomatitis mild, 3 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Nausea severe, 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Diarrhea grade 3, 1 patient
DLT
2800 mg/m2 1 times / week multiple, intravenous
Dose: 2800 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2800 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Diarrhea grade 3-4, 2 patients
DLT
3000 mg/m2 1 times / week multiple, intravenous
Dose: 3000 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3000 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Diarrhea grade 3-4, 2 patients
DLT
3250 mg/m2 1 times / week multiple, intravenous
Dose: 3250 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3250 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Irritation skin 12%
Disc. AE
0.5 % 1 times / day multiple, topical
Recommended
Dose: 0.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Abnormal dreams below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Accidental exposure to product below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Adrenal mass below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anxiety below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arthralgia below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arthropod sting below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Basal cell carcinoma below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Blood blister below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Body temperature increased below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Burning sensation below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cellulitis below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cheilitis below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Chronic obstructive pulmonary disease below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Decubitus ulcer below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dermatitis allergic below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diverticulum below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspepsia below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dysuria below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Emergency care examination below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Eye haemorrhage below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Eye pruritus below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Feeling of body temperature change below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Folliculitis below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Foot deformity below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fungal infection below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gastrooesophageal reflux disease below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gingival pain below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gout below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemangioma below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemorrhage urinary tract below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hernia below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypersensitivity below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Influenza below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Laceration below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Local swelling below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lymphadenopathy below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Malaise below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Muscle rupture below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Musculoskeletal pain below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nasal congestion below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Neck pain below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oral herpes below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oral surgery below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pain in extremity below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Photophobia below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pollakiuria below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Polymyalgia rheumatica below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Post inflammatory pigmentation change below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Productive cough below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Psychotic disorder below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pulmonary mass below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Rhinorrhoea below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Scab below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Seasonal allergy below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Seborrhoea below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Sinus disorder below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Skin discomfort below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Skin tightness below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Skin ulcer below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Syncope below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Syringe issue below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Temperature intolerance below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Temporal arteritis below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Transitional cell carcinoma below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tunnel vision below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Urticaria below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vertigo below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vessel puncture site haematoma below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Visual acuity reduced below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Wound drainage below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pain below serious, 11 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Abdominal pain upper below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Blister below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dermatitis seborrhoeic below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Eye pain below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Herpes zoster below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hyperhidrosis below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypoaesthesia below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Infection below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pneumonia below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tenderness below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Sleep disorder below serious, 22 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Back pain below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diarrhoea below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Eye irritation below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fatigue below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Skin haemorrhage below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bronchitis below serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness below serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Eye swelling below serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dermatitis below serious, 447 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Acne below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fall below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nasopharyngitis below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nausea below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Photosensitivity reaction below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemorrhage below serious, 7 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Abdominal hernia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Adhesion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Angioplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Aortic occlusion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arterial occlusive disease serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arteriosclerosis coronary artery serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arthritis infective serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Atrial tachycardia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Atrial thrombosis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bacteraemia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Basal cell carcinoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Basilar artery stenosis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Benign salivary gland neoplasm serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Binge drinking serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Blood glucose increased serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bronchopneumonia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bursa disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cardiac disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Chest discomfort serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cholecystectomy serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cholecystitis infective serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cognitive disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Colitis ischaemic serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Colorectal cancer serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Completed suicide serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Confusional state serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Coronary angioplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Coronary artery stenosis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cystitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Delirium tremens serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dementia vascular serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Device toxicity serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diffuse large B-cell lymphoma stage IV serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Disorder peripheral vascular serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Disorder vestibular serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspnoea exertional serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Elective procedure serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Electrocardiogram abnormal serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Endocarditis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Epilepsy serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Erectile dysfunction serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Exostosis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Femoral artery occlusion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Generalised oedema serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Goitre serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemangioma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemoglobin decreased serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemoptysis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemorrhage subarachnoid serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemorrhoids serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hepatitis alcoholic serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hernia inguinal serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hip arthroplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypoaesthesia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Impaired gastric emptying serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Inappropriate antidiuretic hormone secretion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Incision site cellulitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Intentional overdose serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Iron deficiency serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Knee arthroplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Labile hypertension serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Limb injury serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lower limb fracture serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Medical device removal serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Mental disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Metastases to central nervous system serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Metastatic squamous cell carcinoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Muscular weakness serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Myocardial ischaemia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nephropathy serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Neuroendocrine carcinoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Obstruction gastric serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oesophageal obstruction serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oesophagogastric fundoplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Palpitations serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pancreatitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Parotidectomy serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pericarditis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Periprosthetic fracture serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pleural effusion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Post-traumatic stress disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Postoperative fever serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Procedural nausea serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Procedural pain serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Prostate cancer recurrent serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Prostatic haemorrhage serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Prostatitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Radiation oesophagitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Rash serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Renal cancer metastatic serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Renal cell carcinoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Renal failure chronic serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Respiratory failure serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Salivary gland cancer serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Septic shock serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Suicidal behaviour serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tendonitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Traumatic haematoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Upper respiratory tract infection serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vascular bypass dysfunction serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vertigo positional serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vertigo serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Viral infection serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vomiting serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
White blood cell count increased serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Wound treatment serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Osteoarthritis serious, 10 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fall serious, 11 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Alcohol abuse serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anaemia serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Aortic aneurysm serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arrhythmia serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Brain neoplasm serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cardio-respiratory arrest serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cholelithiasis serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diabetes mellitus inadequate control serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspnoea serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gastritis serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hip fracture serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hydronephrosis serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hyperglycaemia serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Infection serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
International normalised ratio increased serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Intestinal obstruction serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Meniscus injury serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Mental status changes serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Orthostatic hypotension serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Parkinson's disease serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Renal cancer serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Road traffic accident serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Squamous cell carcinoma serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Ventricular tachycardia serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arthralgia serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Atrial flutter serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Clostridium difficile infection serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Depression serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Failure to thrive serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hyponatraemia serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Malignant melanoma serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Non-cardiac chest pain serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pulmonary embolism serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Suicidal ideation serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dementia serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lung neoplasm malignant serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Transient ischaemic attack serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Transient ischaemic attack serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Angina unstable serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dehydration serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Prostate cancer serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Urinary tract infection serious, 6 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cardiac failure congestive serious, 7 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Chronic obstructive pulmonary disease serious, 9 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nausea grade 1-2, 2 patients
111.6 mg/m2 1 times / day steady, oral
RP2D
Dose: 111.6 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 111.6 mg/m2, 1 times / day
Sources:
unhealthy, 54 years
Health Status: unhealthy
Age Group: 54 years
Sex: M+F
Sources:
Fatigue grade 1-2, 3 patients
111.6 mg/m2 1 times / day steady, oral
RP2D
Dose: 111.6 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 111.6 mg/m2, 1 times / day
Sources:
unhealthy, 54 years
Health Status: unhealthy
Age Group: 54 years
Sex: M+F
Sources:
Diarrhoea grade 1-2, 4 patients
248 mg/m2 1 times / day steady, oral
RP2D
Dose: 248 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 248 mg/m2, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Fatigue grade 1-2, 4 patients
248 mg/m2 1 times / day steady, oral
RP2D
Dose: 248 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 248 mg/m2, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Vomiting grade 1-2, 5 patients
248 mg/m2 1 times / day steady, oral
RP2D
Dose: 248 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 248 mg/m2, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Nausea grade 3, 1 patient
248 mg/m2 1 times / day steady, oral
RP2D
Dose: 248 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 248 mg/m2, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Thrombocytopenia grade 3, 1 patient
248 mg/m2 1 times / day steady, oral
RP2D
Dose: 248 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 248 mg/m2, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Granulocytopenia grade 4, 1 patient
248 mg/m2 1 times / day steady, oral
RP2D
Dose: 248 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 248 mg/m2, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Diarrhea grade 3-4, 3 patients
DLT
139.5 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 139.5 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 139.5 mg/m2, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Granulocytopenia grade 4, 4 patients
DLT
279 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 279 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 279 mg/m2, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diarrhea grade 3-4, 3 patients
DLT
124 mg/m2 1 times / day steady, oral
Dose: 124 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 124 mg/m2, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 3110 uM]
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
weak
yes
Drug as victimTox targets
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
1977 Dec
[Experience of a combination chemotherapy consisting of 5-FU, MMC, and FT-207--side effects against kidney].
1983 Sep
[A case of variant angina induced by 5-fluorouracil and Tegafur].
1988 Nov
[Macrocytic anemia as a possible adverse effect of fluoropyrimidines].
1990 Aug
5-Fluorouracil-induced Raynaud's phenomenon.
1998 Nov
Leukoencephalopathy induced by chemotherapy with tegafur, a 5-fluorouracil derivative.
1998 Nov
Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
1999 Mar
Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.
2000 Apr
Transient splenic accumulation of Tc-99m HMDP caused by megaloblastic anemia.
2000 Dec
Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
2000 Dec 15
Phase II study of combined 5-fluorouracil/ Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer.
2001 Feb
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
2001 Feb 1
Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.
2001 Feb 1
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
2001 Feb 1
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
2001 Feb 15
Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
2001 Feb 15
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.
2001 Feb 15
Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil.
2001 Feb 15
Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
2001 Feb 9
Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer.
2001 Jan
Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer.
2001 Jan
Rapidly progressive glomerulonephritis and carcinoma of the hypopharynx.
2001 Jan
Crystallization and preliminary X-ray study of pig liver dihydropyrimidine dehydrogenase.
2001 Jan
Toward a biologically based dose-response model for developmental toxicity of 5-fluorouracil in the rat: a mathematical construct.
2001 Jan
Toward a biologically based dose-response model for developmental toxicity of 5-fluorouracil in the rat: acquisition of experimental data.
2001 Jan
Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial.
2001 Jan
Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer.
2001 Jan 1
Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance.
2001 Jan 1
Hydroxylamine-containing inhibitors of polyamine biosynthesis and impairment of colon cancer cell growth.
2001 Jan 15
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase.
2001 Jan 15
Monohydroxylation and esterification as determinants of the effects of cis- and trans-9-octadecenoic acids on the permeation of hydrocortisone and 5-fluorouracil across hairless mouse skin in vitro.
2001 Jan 16
The changing face of chemotherapy in colorectal cancer.
2001 Jan 5
Antioxidants enhance the susceptibility of colon carcinoma cells to 5-fluorouracil by augmenting the induction of the bax protein.
2001 Mar 10
Uracil salvage pathway in PC12 cells.
2001 Nov 15
[Thymidylate synthase gene promoter polymorphism in patients with advanced head and neck cancer treated by radio- and 5-fluorouracil chemotherapy].
2006
Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy.
2006 Aug 11
An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer.
2006 Jul 17
An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer.
2007 Apr 23
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
2007 Aug 6
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
2007 Feb 26
5-Fluorouracil incorporated into the tissue RNA of human and rat bladder carcinoma after administration of 1-(2-tetrahydrofuryl)-5-fluorouracil combined with uracil.
2008 Apr
The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.
2008 Apr
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
2008 Jan 24
Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
2010 Jan
Formulation and physicochemical characterization of poly(epsilon-caprolactone) nanoparticles loaded with ftorafur and diclofenac sodium.
2010 Jan 1
[Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].
2010 Jan-Feb
A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
2010 May 15
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+.
2010 Sep 13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Zebrafish (Danio rerio) embryos as a model for testing proteratogens.
2011 Mar 15
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Fluorouracil is recommended for administration either as an intravenous bolus or as an intravenous infusion, but may also be used topically http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
Recommended Dosage for Adenocarcinoma of the Colon and Rectum: The recommended dose of fluorouracil, administered in an infusional regimen in combination with leucovorin alone, or in combination with leucovorin and oxaliplatin or irinotecan, is 400 mg/m2 by intravenous bolus on Day 1, followed by 2400 mg/m2 to 3000 mg/m2 intravenously as a continuous infusion over 46 hours every two weeks. The recommended dose of fluorouracil, if administered in a bolus dosing regimen in combination with leucovorin, is 500 mg/m2 by intravenous bolus on Days 1, 8, 15, 22, 29, and 36 in 8-week cycles.
Route of Administration: Intravenous
Fluorouracil treatment (0.4uM) inhibited LXA4 secretion in colorectal cancer RKO cells
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:48:23 GMT 2025
Edited
by admin
on Mon Mar 31 17:48:23 GMT 2025
Record UNII
U3P01618RT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Fluorouracil
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
5-Fluorouracil
WHO-IP  
Preferred Name English
2,4(1H,3H)-PYRIMIDINEDIONE, 5-FLUORO-
Systematic Name English
ADRUCIL
Brand Name English
FLUOROURACILUM [WHO-IP LATIN]
Common Name English
5-FU
Code English
PHTHORURACIL
Common Name English
5-FLUOROURACIL [IARC]
Common Name English
FLUCYTOSINE IMPURITY A [EP IMPURITY]
Common Name English
EMTRICITABINE IMPURITY F [WHO-IP]
Common Name English
QUEROPLEX
Common Name English
Fluorouracil [WHO-DD]
Common Name English
EFUDEX
Brand Name English
5-FLUOROPYRIMIDIN-2,4(1H,3H)-DIONE [WHO-IP]
Systematic Name English
5-FLUORURACIL
Common Name English
FLUOROURACIL [ORANGE BOOK]
Common Name English
FLUOROURACIL [EP MONOGRAPH]
Common Name English
5 FU
Code English
CARAC
Brand Name English
TOLAK
Systematic Name English
RO-29757
Code English
FLUOROURICIL
Common Name English
FLUOROURACIL [MI]
Common Name English
RO-2-9757
Code English
FLUOROURACIL [USP-RS]
Common Name English
Folfox component fluorouracil
Common Name English
FLUOROURACIL [VANDF]
Common Name English
5 FLUOROURACIL
Systematic Name English
FLUOROURACIL [USAN]
Common Name English
FLUCYTOSINE IMPURITY A [WHO-IP]
Common Name English
FLUOROURACIL [WHO-IP]
Common Name English
FLUOROURACIL [JAN]
Common Name English
NSC-19893
Code English
RO 2-9757
Code English
FLUOROURACIL [HSDB]
Common Name English
5-FLUOROURACIL [WHO-IP]
Common Name English
FLUOROURACIL [MART.]
Common Name English
5-FLUORO-URACIL
Systematic Name English
FLUOROURACIL [USP MONOGRAPH]
Common Name English
fluorouracil [INN]
Common Name English
FLUOROPLEX
Brand Name English
Classification Tree Code System Code
LIVERTOX NBK548781
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
NCI_THESAURUS C1557
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
WHO-ATC L01BC02
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
IARC 5-Fluorouracil
FDA ORPHAN DRUG 40589
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 13.4
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
WHO-ATC L01BC52
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
FDA ORPHAN DRUG 42289
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
WHO-VATC QL01BC02
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
NDF-RT N0000000233
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
NCI_THESAURUS C2021
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
WHO-VATC QL01BC52
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
EU-Orphan Drug EU/3/00/004
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
FDA ORPHAN DRUG 32088
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
NDF-RT N0000175595
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
FDA ORPHAN DRUG 131799
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
Code System Code Type Description
NSC
19893
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
MERCK INDEX
m5483
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY Merck Index
FDA UNII
U3P01618RT
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
WIKIPEDIA
FLUOROURACIL
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-085-6
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
FLUOROURACIL
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY Description: A white or almost white, crystalline powder. Solubility: Sparingly soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Cytotoxic drug. Storage: Fluorouracil should be kept in a tightly closed container, protected from light. Additional information: Fluorouracil melts at about 282?C with decomposition. CAUTION: Fluorouracil must be handled with care, avoiding contact with the skin and inhalation of airborne particles. Definition: Fluorouracil contains not less than 98.5% and not more than 101.0% of C4H3FN2O2, calculated with reference to the dried substance.
MESH
D005472
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
DRUG CENTRAL
26
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
ChEMBL
CHEMBL185
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
NCI_THESAURUS
C505
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
EVMPD
SUB07721MIG
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
PUBCHEM
3385
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
EPA CompTox
DTXSID2020634
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
RS_ITEM_NUM
1279000
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
CHEBI
46345
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
DAILYMED
U3P01618RT
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
HSDB
3228
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
IUPHAR
4789
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
RXCUI
4492
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY RxNorm
SMS_ID
100000091592
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
LACTMED
Fluorouracil
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
CAS
51-21-8
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
INN
1421
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
DRUG BANK
DB00544
Created by admin on Mon Mar 31 17:48:23 GMT 2025 , Edited by admin on Mon Mar 31 17:48:23 GMT 2025
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
Down-regulation of ABCB5?resulted in a gain of drug sensitivity to camptothecin 10-OH, 5-fluorouracil, and mitoxantrone.
EXCRETED UNCHANGED
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TRANSPORTER -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
METABOLITE ACTIVE -> PRODRUG
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
METABOLITE INACTIVE -> PARENT
MAJOR
PRODRUG -> METABOLITE ACTIVE
METABOLITE INACTIVE -> PARENT
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
Related Record Type Details
ACTIVE MOIETY